Introduction
Overweight and obesity are defined as the accumulation of fat in body tissues that might impair overall health. 1 Many studies have demonstrated a positive association between obesity and periodontitis and suggested that obesity-related inflammation might promote periodontitis by secretion of inflammatory markers by the adipose tissue, which might subsequently increase gingival inflammation. 2, 3 The association between obesity and periodontal disease is based on the amassing of white adipose tissue (WAT) and increased secretion levels of adipokines from WAT.
WAT is an energy storage organ with some metabolic activities, participating in the endocrine and secretory systems. 4 It secretes several immune-modulator adipokine molecules, such as adiponectin, leptin, visfatin, resistin, chemerin, tumor necrosis factoralpha (TNF-α), interleukin-1β (IL-1β), and IL-6. 4 It has been found that these molecules are involved in a wide range of physiologic and pathological processes, including immunity and inflammation. 5 Thus, cytokines and hormones released from adipose tissue might play a role in the destruction of periodontal tissue by inducing hyper-inflammatory responses.
Visfatin is identified as a new adipokine, which is involved in the early development of the B-cell growth factor and cytokine-like effects. 6 Visfatin is a 52-kDa protein that increases pre-B-cell colony release from lymphocytes. 6 It is a multi-potential mediator that functions as a growth factor, cytokine, an enzyme with a role in energy metabolism, and as a proinflammatory mediator. 6 Visfatin is mainly released from adipose tissue, especially by macrophages, and can also be released from lymphocytes, dendritic, muscle, periodontal ligament and bone marrow cells. 7, 8 Visfatin has an important role in the regulation of immune response. Visfatin inhibits neutrophil apoptosis during infection and inflammation, and increases TNF-α, IL-1β, and IL-6 levels. 6 Visfatin is also known as nicotinamide phosphoribosyltransferase. 6 The expression of visfatin is increased under inflammatory conditions, such as rheumatoid arthritis, cardiovascular diseases, type 2 diabetes mellitus, and periodontal disease. 9 Several studies have investigated the link between periodontitis and obesity, and these investigations have also shown that obesity and periodontitis are also related to gingival crevicular fluid (GCF) levels of adipokines. [2] [3] [4] 9 Increased adipocyte levels, such as from visfatin, cause secretion of cytokines, which are known to play an important role in periodontitis and might trigger periodontitis formation and development. 
Inclusion and exclusion criteria
Inclusion criteria for all patients in both groups were: having >22 natural teeth; no systemic diseases; being cooperative; having BMI>30 with waist circumference (WC)>88 cm for females and >102 cm for males for obese patients; and >20-years-old.
The following exclusion criteria were considered: localized chronic periodontitis; receiving periodontal therapy/surgery in the last 6 months; pregnancy or use of any hormone therapy; history of antibiotic or antiinflammatory drug therapy within the last 6 months; current and former smoker; lactating; aggressive periodontitis; and periapical pathologies.
At the beginning of the study, detailed anamnesis was taken from all participants, and age, gender, oral hygiene habits, and any systemic conditions were recorded for each patient. GCF sampling and laboratory analysis GCF samples were collected 1 week after the clinical measurements taken at baseline and repeated 3 months later. In the healthy group, samples were obtained from maxillary anterior four teeth exhibiting PD<3 mm without CAL or BOP. Four sites from each tooth were used for GCF sampling. In the GCP group, GCF samples were collected from four teeth with BOP, PD≥5 mm, CAL≥5 mm, and 30% bone loss. Before sampling, the area was isolated with cotton rolls to prevent saliva contamination; the area was then slightly air-dried. GCF was collected using paper strips (Periopaper, ProFlow Inc., Amityville, NY, USA) and the volume of fluid in each strip was determined using a calibrated Periotron 6000 (Periotron™ 6000, Proflow Inc., Amityville, NY, USA). Strips were inserted into the crevice until mild resistance was felt, and were put to one side in stasis for 30 seconds. Strips contaminated with blood or saliva were discarded. Samples were immediately placed into microcentrifuge tubes and stored at -20°C until analyzed. Levels of visfatin (Phoneix Pharmaceuticals Inc., Burlingame, CA, USA), TNF-α (eBioscience Inc., Affymetrix, Santa Clara, CA, USA), and IL-6 (eBioscience Inc., Affymetrix, Santa Clara, CA, USA) in GCF samples were determined using an enzyme-linked immunosorbent assay (ELISA) (ELx800, Biotek, Winooski, VT, USA). For laboratory analysis, 600 μl of phosphate buffered saline (PBS, pH 7.4) was added to each tube containing sample strips. Each tube was vortex-mixed for 60 seconds and centrifuged for 5 minutes at 8000 rpm in order to elute.
The assay was performed using recombinant human standards according to the manufacturer's instructions.
Optical density was measured at 450 to 490 nm. GCF results were reported as the total amount (pg/ml). Comparison of data between obese and nonobese groups Individuals from the O group were older than in the nO group (P<0.002). Most of the O group (98%) was female, whereas around half (52.6%) of the nO group was female (p<0.001). Additionally, there was a statistically significant difference between groups in terms of tooth brushing frequency (p<0.036) and interproximal cleaning (p<0.007) ( Table 1 ).
There were differences betwen groups for anthropometric measurements (p<0.002). At baseline and 3 rd month, weight, BMI and WC were higher in the O group than in the nO group (p<0.001) ( Table 2 ).
The O group had higher total cholesterol (p<0.029) and triglyceride levels than the nO group (p<0.05) ( Table 2 Comparison of data among O-Ctrl, nO-CP, O-Ctrl, and O-CP groups
The demographic values of the study population are given in Table 3 . There were significant differences reported that the measurements of periodontal indices were higher in obese than non-obese subjects. 13, 15, 16 In the present study, PI, GI, PD, CAL, and BOP Adipocytes cause hyperinflammatory responses by over expressing adipokines and adipocytokines 9 .
Accordingly, it has been proposed that the increased amount of adipose tissue in obese individuals triggers the development of periodontitis.
Visfatin is thought to have insulin-like effects, particularly those that lower plasma glucose levels. 7, 18 Also, it has been suggested that visfatin release in fat cells is independently associated with obesity and metabolic syndrome. 8, 18 The abundance of adipose tissue in these patients is responsible for elevated levels of visfatin. 18, 19 In our study, the mean GCF visfatin level was 11.71 pg in the obese group and 8.81
pg in the nO group. However, this difference was not statistically significant. The authors reported that the level of visfatin was higher in obese women than in non-obese participants. 20 The same study also reported a correlation with plasma visfatin and body weight reduction using an exercise program. 20 Similarly, in the present study, the total amount of visfatin in GCF was significantly increased in patients with O-CP compared to the other groups. As predicted, significant decreases in GCF levels of visfatin were observed in both the O-Ctrl and O-CP groups throughout the study period. The present study findings are in line with recent studies. 7, 8, 21 Pradeep, et al. 8 (2011) evaluated the relationship between the serum and GCF concentrations of visfatin and periodontal diseases, concluding that visfatin concentration increased with disease severity in the serum and GCF. In addition, the concentration of visfatin was higher in patients with GCP and type 2 diabetes mellitus (T2DM) compared to systemically healthy individuals with periodontal disease. 8 Mohamed, et al. 22 (2015) reported a positive correlation between PD and visfatin levels in GCF, and they found that visfatin increased significantly the number of diseased sites. Türer, et al. 23 (2015) showed that GCF and serum visfatin levels are higher in patients with chronic periodontitis than those with gingivitis and healthy controls. They also reported that visfatin levels were significantly decreased following periodontal treatment. Ghallab, et al. 21 (2015) detected significantly higher visfatin mRNA and protein expression in patients with CP+T2DM compared to controls, which is in agreement with a previous study.
It has been reported that salivary visfatin levels increase in patients with periodontal disease and that there is a relationship between salivary visfatin concentration and periodontal infection. 24 A recent study reported significantly higher expression of visfatin, NF-κB, PI3k, TNF-α, and IL-1β in gingivitis and periodontitis groups compared to healthy individuals.
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These authors suggest that increased visfatin levels play a role in the pathogenesis of periodontitis.
TNF-α and IL-6, which are known as tissue destruction mediators, function as pro-inflammatory cytokines, and their levels increase during inflammation. 26 In GCP, these cytokines are thought to play an important role on the pathogenesis of the disease by stimulating bone resorption. 26 In patients with severe periodontitis, corpuscles and adipocytes in the liver have been proposed as IL-6 sources. 
Conclusion
In conclusion, the results of this study suggest that visfatin and IL-6 levels might play a role in the pathogenesis of obesity and periodontal disease and that these can be used as reliable markers for monitoring the progress of both diseases. Moreover, our findings demonstrate that, in addition to obesity, lipid profiles can be associated with periodontitis in systemically healthy people.
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